

Review

Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors

Abigail Cheever , Michelle Townsend  and Kim O'Neill * 

Department of Microbiology and Molecular Biology, Brigham Young University, Provo, UT 84602, USA

* Correspondence: kim_oneill@byu.edu; Tel.: +1-801-422-2449

Abstract: Chimeric antigen receptor (CAR) T cells are an exciting advancement in cancer immunotherapy, with striking success in hematological cancers. However, in solid tumors, the unique immunosuppressive elements of the tumor microenvironment (TME) contribute to the failure of CAR T cells. This review discusses the cell populations, cytokine/chemokine profile, and metabolic immunosuppressive elements of the TME. This immunosuppressive TME causes CAR T-cell exhaustion and influences failure of CAR T cells to successfully infiltrate solid tumors. Recent advances in CAR T-cell development, which seek to overcome aspects of the TME immunosuppression, are also reviewed. Novel discoveries overcoming immunosuppressive limitations of the TME may lead to the success of CAR T cells in solid tumors.

Keywords: tumor microenvironment; TME; chimeric antigen receptor; CAR T cell; cancer; immunotherapy; solid tumor; immunosuppression; CAR T-cell exhaustion



Citation: Cheever, A.; Townsend, M.; O'Neill, K. Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors. *Cells* **2022**, *11*, 3626. <https://doi.org/10.3390/cells11223626>

Academic Editors: Graziana Digiacomio and Andrea Cavazzoni

Received: 21 October 2022

Accepted: 15 November 2022

Published: 16 November 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

1.1. CAR T Cells

Cancer immunotherapy is a growing and important field, shaping the future of cancer treatment. One category of immunotherapy seeks to selectively kill cancer cells through specific targeting of tumor-associated or tumor-specific antigens using chimeric antigen receptors (CARs). CARs are a combination of the variable binding portion of an antibody with the signaling and costimulatory domains of a T-cell receptor. The variable binding portion is typically a single-chain variable fragment (scFv), comprised of a portion of the heavy and light chain of an antibody (Figure 1). In a CAR, an scFv is connected to a transmembrane domain by a hinge region. It also includes intracellular signaling domains: the primary signaling domain, CD3 ζ , and costimulatory domains, commonly CD28 and 4-1BB [1]. This CAR construct allows CAR T cells to be activated with a single binding event, eliminating the need for coreceptor interaction, which is necessary for activation of normal T cells. Upon binding, the CD8+ T-cell cytotoxic capabilities, including directional release of perforin and granzymes and Fas/FasL interactions, are then activated, killing the target cell [2,3].

CAR T-cell therapies were first FDA approved in 2017 for treatment of pediatric and young adult acute lymphoblastic leukemia (ALL) and later other B cell malignancies. Tisagenlecleucel (Kymriah[®]), developed by Novartis, was the first to be approved, with Axicabtagene ciloleucel (Yescarta[®]) developed by Kite Pharma following several months later [4]. After this initial success, research applying CAR T cells to many other cancers increased dramatically in the immunotherapy community. Currently, there are six FDA approved CAR T-cell therapies, all for hematological cancers (Abecma[®], Breyanzi[®], Carvykti[®], Kymriah[®], Tecartus[®], and Yescarta[®]), with an overall response rate above 80% for B cell malignancies [5–7]. The most recently approved CAR T-cell therapy, ciltacabtagene autoleucel, has two binding domains to B-cell maturation antigen (BCMA), a B-cell marker that becomes over-expressed in multiple myeloma [8]. The success of this

treatment was reported at 97% overall response rate and 67% complete response rate [8]. CAR T-cell therapy is quickly becoming a more common treatment option for patients with relapsed and refractory hematological cancers [9]. CAR T-cell research continues with over 500 clinical trials currently [5]. These CAR T cells have many modifications to alter their mechanisms and apply them to a variety of cancer types.




Figure 1. CAR T-cell structure and effector mechanism. CAR T cells are composed of a CD8⁺ T cell with a CAR construct, which is composed of scFv, transmembrane, and activation domains. CAR T cells bind to their specific antigen on cancer cells, activating cytotoxic function (directional release of perforin/granzymes or Fas/FasL interaction), killing the cancer cell.

Despite the impressive success of CAR T-cell therapy in blood cancers and the plethora of research applying the principle to other cancers, CAR T cells have yet to be as successful in solid tumors. Solid tumors have an influential tumor microenvironment (TME), which presents obstacles to CAR T-cell homing to the tumor, activation, and longevity [10]. The characteristics of the TME, its mechanisms of immunosuppression, and how that affects CAR T-cell efficacy will be discussed in this review article.

1.2. Tumor Microenvironment

The heterogeneous components of the TME include a variety of cells, matrix proteins, and secreted factors. Cells in the TME include cancer cells, cancer-associated fibroblasts (CAFs), and immune cells, including tumor-associated macrophages (TAMs), natural killer (NK) cells, myeloid progenitor cells, myeloid-derived tumor suppressor cells (MDSCs), effector and regulatory T cells, dendritic cells (DCs), and neutrophils (Figure 2). Other cell types are present depending on the tumor location and cancer type. There is also an extracellular matrix (ECM) comprised of stromal cells, fibrous proteins, glycoproteins, proteoglycans, and polysaccharides, which provides structure to the tumor and gives some separation between other tissue [11]. The ECM also affects cell differentiation, proliferation, and metastasis [12,13]. Secreted factors, including cytokines, chemokines, and other proteins, are secreted by cancer and immune cells into the TME as well [14]. These secreted factors affect the TME in a variety of ways, including trafficking and polarization of immune cells and their activation or repression, cell growth and proliferation, and the inflammatory state of the TME [15].




Figure 2. The heterogeneous tumor environment. Tumors are comprised of a variety of cell types, as shown above. The ECM and CAF form a barrier that separates the tumor from the surrounding tissue. The vasculature of the TME often is insufficient for the constant proliferation and tumor growth.

Another physical characteristic of the TME is its irregular vasculature. Angiogenesis is considered a hallmark of cancer, and as tumors develop, a hypoxic state due to increased tumor mass without accompanying nutrient delivery triggers an “on switch” for angiogenesis [16]. Angiogenesis initiation is also influenced by secreted factors from surrounding cancer and immune cells and is often chronically activated in tumors [17]. The blood vessels produced by chronic activation of angiogenesis are commonly irregular, leading to areas of high and low circulation, excessive capillary branching, and blood vessel leakage, which can greatly affect cell populations and metastasis [18].

The players and ecosystem of the TME greatly influence the immunosuppression crucial to tumor growth and metastasis. This immunosuppression not only plays a role in the development of the tumor but also affects immunotherapy success. Though this discussion only scratches the surface of the complexities of the TME, the mechanisms of immunosuppression in the TME and its effect on CAR T-cell therapy will be further discussed.

2. Mechanisms for Immunosuppression

2.1. Immunosuppressive Cell Populations

As previously mentioned, there are many different immune cell populations present in the TME. Some are tumor-antagonizing, while many are tumor-promoting [19]. Tumor-antagonizing immune cells recognize the cancer cells as damaged, which stimulates an anti-tumor response.

Among these anti-tumor immune cell populations are CD8+ T cells, which have cytotoxic abilities to kill cancer cells when activated and are considered the key effector cell against cancer [20]. CD4+ T cells provide help and stimulation to CD8+ T cells and orchestrate the immune response through release of proinflammatory cytokines and chemokines [21]. NK cells are important for immunosurveillance of tumors, and they

also have cytotoxic abilities similar to CD8+ T cells [22]. DCs are professional antigen-presenting cells (APCs) and mainly function in the TME to present antigen and give costimulation to T cells [23]. Macrophages are plastic cells and can be polarized to an M1-like or M2-like phenotype. M1 macrophages are pro-inflammatory macrophages that have anti-tumor function through phagocytosis of tumor cells and production of proinflammatory cytokines and reactive oxygen species [24]. Finally, neutrophils are important for releasing proinflammatory cytokines and contributing to a cytotoxic effect against cancer cells through phagocytosis, release of neutrophil extracellular traps, and antibody-dependent cellular-cytotoxicity (ADCC) [25].

In an ideal world, these tumor-antagonizing immune cells function to eliminate cancer cells as tumors form and prevent progression and metastasis [19]. However, in many cases, the variety of immunosuppressive mechanisms employed by the tumor—from metabolic changes to angiogenesis to immunosuppressive cytokine release—reduce the efficacy of anti-tumor immune cells and even turn them away from the TME [26]. The TME is catered to support pro-tumor immune cells, which assist in the suppression of an anti-tumor immune response.

TAMs are an influential pro-tumor immune cell population and comprise up to 50% of the tumor mass in some cancers [27]. Macrophages can polarize to become M1-like or M2-like in response to their environment. The TME both polarizes macrophages in the tumor to become M2 and recruits other M2 macrophages to the tumor [24,28]. M2-polarized macrophages induce immunosuppression, angiogenesis, tissue healing, and growth and downregulate inflammatory or M1 functions [29]. These characteristics of M2 macrophages that TAMs often have support tumor growth and metastasis. TAMs also tend to accumulate in necrotic or low-oxygen areas of tumors [30]. This accumulation plays a role in the pro-angiogenic effect of TAMs. TAMs release growth factors, including VEGF, PDGF, and TGF- β , as well as the angiogenic factor thymidine phosphorylase and other angiogenesis-modulating enzymes [27,31–33]. This directly influences the irregular angiogenesis, which is characteristic of the TME. Growth factors released by M2 macrophages also promote uncontrolled growth of cancer cells and increase tumor progression [34]. The cytokine profile released by TAMs (discussed in greater detail in the following section) interacts with other immune cells, preventing activation and recruitment of effector T cells, inducing Treg differentiation, and overall suppression of the inflammatory immune response. Higher levels of M2 macrophages are correlated with a poor prognosis in cancer patients [35]. These attributes demonstrate that TAMs greatly influence the immunosuppressive state of the TME and are highly significant in cancer progression.

MDSCs are immature myeloid cells that take one of two forms: (1) mononuclear MDSCs (M-MDSCs) which are quite similar and can later become TAMs, or (2) polymorphonuclear MDSCs (PMN-MDSCs), which phenotypically resemble neutrophils [36]. MDSCs affect the TME in a variety of ways similar to TAMs; however, their most prominent feature is their immunosuppression, especially inhibiting T-cell function [37]. They are effective at killing and inducing T-cell anergy by expressing high levels of programmed death ligand-1 (PDL-1), release of immunosuppressive cytokines, and sequestering essential amino acids and nutrients [36]. One important metabolic immunosuppressive mechanism of MDSCs is their accumulation of cysteine, which is necessary for T-cell activation. The depleted amount of cystine in the TME due to MDSC sequestering prevents T-cell activation—both native T cells and CAR T cells [38,39]. In clinical trials of CAR T cells, lower levels of MDSCs present in the tumor were correlated with more success of the CAR T-cell treatment, demonstrating the inhibitory effect MDSCs have on CAR T cells in the TME [40].

Regulatory T cells (Tregs) are immunosuppressive T cells most often characterized by expression of CD4, CD25, and FoxP3 [41]. In the body, they play an important role in maintaining homeostasis in immune response and influencing peripheral tolerance, which allows them to play a key role in preventing autoimmunity [42,43]. In cancer, the role of Tregs is complicated, but in several cancers, especially solid tumor cancers, the Treg popula-

tion is increased during tumor progression and is correlated with a poor prognosis [44,45]. The role of Tregs is two sided. Tregs play a role in preventing chronic inflammation, which may be favorable in tumor prevention because, in some cancers, the chronic inflammatory state can induce mutations in cancer cells leading to tumor progression [46]. However, Tregs are also key players in tumor escape and immunosuppression by inhibiting cytotoxic T-cell elimination of cancer cells and through release of immunosuppressive cytokines (discussed further in the following section) [47].

CAFs contribute to a significant percentage of tumor mass [34]. Fibroblasts in normal tissue are a small proportion of cells that contribute to formation of connective tissue [48]. In tumors, CAFs play several roles but are primarily responsible for extracellular matrix regulation, which in turn affects tumor growth, immune invasion, and metastasis [49]. They are a heterogenous population of cells, which also release secreted factors and chemokines to affect the metabolism, angiogenesis, and immunosuppression of the TME [50,51]. Perhaps one of their most crucial immunosuppressive roles is as a physical barrier preventing immune cell infiltration. CAFs form a “shell” of sorts around the tumor, which is especially effective at preventing T-cell infiltration. A recent study confirms that CD8+ T-cell infiltration in breast cancer tumors is directly correlated with the strength of the CAF barrier, due not only to physical barrier but also due to secreted factors that affect the immunosuppressive effects of the TME [52].

2.2. Secreted Factors

Secreted factors, including cytokines and chemokines, are an essential part of immunosuppression in tumors, as they are a signaling mechanism between cells, especially immune cells. The most relevant cytokines to the TME are controlled by the transcription factors NF- κ B and STAT3 [53]. NF- κ B is important for the formation of inflammatory sites inside the tumor by inducing gene expression of inflammatory cytokines, most notably TNF- α , IL-1, and IL-6 [54]. STAT3 also induces gene expression of inflammatory cytokines and type-1 interferons, though arguably, its most important role is in expression of IL-6 [55]. The interplay between NF- κ B and STAT3 controls a majority of the inflammatory cytokine production in the TME, which alters the immune balance there, recruiting immune cell populations such as TAMs and MDSCs [56].

Pro-tumor immune cells produce anti-inflammatory and immunosuppressive cytokines, which can reduce effector cell function and allow for tumor escape. Notable among these are IL-10 and TGF- β produced by TAMs, MDSCs, and Tregs [57]. IL-10 is important for helper T cells to perform immune surveillance and allow immunosuppressive function and is commonly produced by Tregs [58]. TGF- β is known to be involved in tumor progression, though members of this cytokine family induce a variety of effects on differentiation, metastasis, and tumor invasiveness [59]. Other cytokines/growth factors allow for direct recognition of cancer cells through innate immunity. For example, PDGF-D is secreted by tumor cells and is the ligand for NK cell-mediated recognition of tumor cells [60]. Immunosuppressive and inflammatory cytokines work together and against each other to affect the complex interplay of signaling and directing immune cell function, promoting cancer proliferation, and altering the TME (Table 1 [53]).

Table 1. Common tumor-associated cytokines.

Cytokine/Chemokine	Secreted by	Function
IL-1 β	MDSCs TAMs	Mediates the inflammatory response through inflammasomes Induces cancer cell proliferation
IL-2	T cells NK cells	Promotes T-cell growth Influences Treg differentiation Promotes production of TNF- α and INF- γ
IL-4	CD4+ T cells B cells	Influences M2 macrophage polarization Creates a positive feedback loop in CD4+ T cells to produce more IL-4
IL-6	TAMs MDSCs	Promotes inflammation Can lead to accelerated tumor growth by promoting self-renewal in tumor cells
IL-10	TAMs MDSCs Treg cells CD4+ T cells B cells	Influences M2 macrophage polarization Suppresses dendritic cells Negatively regulates the inflammatory response Stimulates T reg cells
IL-12	TAMs Dendritic cells	Promotes differentiation of T cells Enhances production of INF- γ Influences M1 macrophage polarization
IL-13	CD4+ T cells	Influences M2 macrophage polarization
TNF- α	TAMs T cells NK cells	Influences signaling pathways to promote apoptosis or necrosis Promotes cancer cell proliferation
TGF- β	TAMs MDSCs Treg cells CAFs	Dual role in tumor suppression and promotion Inhibits CD8+ T-cell cytotoxic function Reduces MHC presentation in tumor cells Mediates tumor migration and immune cell infiltration
INF- γ	T cells B cells NK cells Dendritic cells	Dual role in tumor suppression and promotion Activates macrophages Promotes apoptosis Inhibits angiogenesis in the TME

2.3. Metabolic Influences on Immunosuppression

The TME is characterized by an abnormal metabolic profile, which can be highly immunosuppressive. Some of these metabolic differences include insufficient nutrient and oxygen levels and accumulation of metabolic waste.

Cancer cells have a high demand for virtually every nutrient required for growth and proliferation, which often starves surrounding and invading immune cells of nutrients they need. Notably, glucose and glutamine are shown to be especially needed by cancer cells [61,62]. Cancer cells perform glycolysis for a majority of their energy, even in the presence of enough oxygen, in a phenomenon called the Warburg effect [63,64]. This phenomenon was first observed in the 1920s by Otto Warburg, when he and his colleagues observed the dramatically increased amount of glucose being consumed by tumor cells compared to surrounding tissue [65,66]. Glutamine's necessary role in the synthesis of nucleotides and amino acids leads to significant use of glutamine in cancer cells as well [67]. Low levels of glucose in the TME can cause immune cells to be activated less and die at greater rates [64]. For example, naïve CD4+ and CD8+ T cells shift to upregulate glycolysis and glutaminolysis when they become activated. However, when glucose and glutamine levels are low in the TME, T cells do not activate as strongly, and Treg differentiation increases as well [68,69]. Other immune cells also require glucose and glutamine for

survival and activation, and competition with cancer cells for these limited resources can cause most immune cells to be suppressed in the TME [68]. Cancer cells are also prone to rapid metabolite adaptation, where they can adjust to the changing metabolite concentrations in the TME, allowing them to not only survive but also outcompete other cells in the area [70].

Insufficient oxygen level, or hypoxia, is common in the TME because extensive proliferation is unsupported by proper blood vessel formation, which affects the function of all cells in the TME, including immune cells [71]. Hypoxia reduces activation of effector cells, including CD8⁺ T cells and NK cells, similarly to insufficient nutrient levels, and can cause their death and reduced cytokine production [72,73]. The decreased oxygen levels in the TME also promote suppressor immune populations, including Treg and M2 macrophages [64,74].

The Warburg effect also affects the acidity of the TME because excessive production of lactic acid, a product of glycolysis, lowers the pH [75]. The acidity of the TME negatively affects immune cell function, resulting in immunosuppression. High levels of lactic acid were shown to induce expression of M2 polarizing genes in macrophages, including *Vegf* and *Arg1*, and they were also able to show that this expression was important to tumor growth in mice [76]. Lactate was also shown to inhibit nuclear factor of activated T cells (NFAT), which is a key activation transcription factor in T cells and NK cells [68]. Not only did high lactate concentration correlate with lower activation markers, but it also was positively correlated with T and NK cell apoptosis and decreased cytokine production [77]. Lactate dehydrogenase also interacts with FoxP3, an important transcription factor for Treg differentiation, allowing Treg cells to have a metabolic edge in surviving the TME [69].

3. Effects of the Immunosuppressive TME on CAR T Cells

CAR T cells are considered “living drugs” because they activate, proliferate, and expand depending on what they are presented with and the environment they are in. This means that the immunosuppressive elements of the TME previously discussed can greatly affect the efficacy of CAR T cells. The TME can limit homing to tumor sites, limit infiltration into the tumors, induce exhaustion, and even impact acquired resistance to CAR T-cell therapy (Figure 3).

3.1. Homing and Solid Tumor Infiltration Difficulties

CAR T-cell therapy is significantly more effective in hematological cancers compared with solid tumor cancers primarily because of “accessibility” [78]. Patient data and in vivo imaging show that after treatment, CAR T cells are often present in high levels in the blood and lymph without successfully infiltrating the tumor [79,80]. Several elements of the TME contribute to the difficulty CAR T cells have in homing to and infiltrating solid tumors. CAR T cells are typically administered intravenously, though injection into the tumor is another option currently being studied. Thus, for CAR T cells to home to the tumor, they must travel through blood vessels. The insufficient vasculature of the TME impairs arrival of CAR T cells in the tumor because of lack of access [78]. This lack of access is also added upon by the “shell” surrounding the tumor comprised of CAFs and ECM [81,82]. Prevention of T-cell accumulation around and in solid tumors has also been shown to be correlated with high levels of MDSCs and TAMs, likely through secretion of inhibitory chemokines [81]. T cells leave the blood vessel and enter tissue through a process called extravasation, which relies on integrins and selectins for T cells to pass through the endothelial cells of the blood vessels [83]. However, studies on non-CAR T cells show that the TME impairs T-cell extravasation through irregular vasculature caused by tumor-induced angiogenesis and by downregulating extravasation mediators (including L-selectins, LFA-1, Mac-1, ICAM-1, and TNF- α) [84,85]. TAMs have also been shown to impair the ability of T cells to infiltrate into tumors. When TAMs were eliminated from a tumor mouse model with PLX3397, an inhibitor of colony-stimulating factor-1 receptor, the CD8⁺ T-cell population increased in strong correlation to macrophage depletion [86]. These

studies demonstrate how T-cell infiltration is inhibited in solid tumors, but it is logical to deduce that CAR T cells would interact similarly because they are simply T cells with modified receptors. Therefore, we conclude that immunosuppression caused by ineffective CAR T-cell infiltration into solid tumors plays a major role in CAR T-cell failure in tumors.




Figure 3. Immunosuppressive effects on CAR T cells. (A) CAR T cells can fail to infiltrate solid tumors due to lack of blood vessel penetration into the tumor, the barrier surrounding the tumor comprised of the ECM and CAFs, and down-regulation of extravasation mediators needed to leave the blood vessels. (B) Metabolic-induced exhaustion caused by increased glycolysis of cancer cells results in low nutrient levels and high waste levels. This metabolic environment impairs T-cell activation and cytotoxic function. (C) Chronic antigen stimulation from abundant cancer cells in the TME can lead to anergy and exhaustion of CAR T cells. (D) Heterogenous cancer cell populations with varying antigens and selective pressure can lead to antigen escape, where cancer cells will evolve not to express the antigen the CAR T cell binds to.

One method that has become a common practice in CAR T-cell testing in animal models and clinical trials is injection of CAR T cells into the tumor rather than intravenous delivery. Some improvement of CAR T-cell homing and infiltration in solid tumors has been seen, but it has not shown a complete fix of the problem [87,88].

3.2. CAR T-Cell Exhaustion

T-cell exhaustion is a phenomenon where T cells experience decreased effector function and a different transcriptional profile, including continuous upregulation of inhibitory receptors [89,90]. T-cell anergy can appear functionally similar to T-cell exhaustion, with similar results of unresponsiveness to antigen, and also is common in the TME. Anergy is believed to be caused by either robust inhibitory costimulatory signaling or weak positive costimulatory signaling when T cells bind to peptide/MHC complexes [90]. CAR T-cell exhaustion is mostly influenced by a lack of oxygen and nutrients in the TME. T cells are sensitive to the metabolic environment in which they find themselves, and studies show that T-cell efficacy is greatly influenced by the metabolic state of the TME [91]. Immune suppressive metabolic elements previously discussed—including hypoxia, nutrient competition, and acidity—cause epigenetic changes to T cells in vivo, which alters their

transcriptome and, thus, function to have significantly impaired anti-tumor abilities [91]. These same immunosuppressive metabolic elements are likely to alter the efficacy of CAR T cells in solid tumors as well.

Tumors have dense concentrations of cancer cells, which in turn creates very high levels of antigen stimulation. CAR T cells thus experience chronic antigen activation, influencing development of exhaustion [92,93]. The mechanism of how repeated antigen stimulation induces an exhaustive or anergic state is not well understood, but recent studies show that inhibition of mitochondrial oxidative phosphorylation leads to epigenetic changes and decreased expression of effector genes [94]. These changes in mitochondrial oxidative phosphorylation also affect mitochondrial depolarization and induce T cells toward terminal exhaustion [93]. Continuous activation also pushes CAR T cells towards exhaustion through increased expression of PD-1, which not only increases chances of death through interaction with PDL-1 on cancer cells but also may alter metabolic reprogramming to push T cells towards an exhausted state, even without direct interaction with PDL-1 expressed on cancer cells [95–98].

Some data show that using less differentiated T cells in CAR T-cell development improves persistence in the TME through greater capacity for proliferation and generation of a long-term memory response with fewer signs of exhaustion [99].

3.3. Antigen Escape in CAR T-Cell Therapy

Limited efficacy of CAR T cells in solid tumors can put selective pressure on the surviving cancer cells to become resistant to CAR T-cell therapy. [100] This can happen through loss of antigen, where the cancer cells mutate to lose the antigen that the CAR T cell recognizes or proliferate from a cell without the antigen that existed from the time of treatment [101]. The mechanisms and incidence of antigen escape-mediated resistance has been extensively reviewed by Lemoine et al. [102]. Increased expression of PD1-L can also affect resistance by killing the CAR T cells in large quantities through overexpression of the ligand [103–105]. Mechanisms of resistance to CAR T cells are still under investigation, and we expect to understand this phenomenon better in the future.

4. CAR T-Cell Advancements and Co-Treatments to Overcome Immunosuppression Roadblocks

4.1. Immune Checkpoint Inhibitors

Checkpoint inhibitors are another cancer immunotherapy that have seen significant success in recent years. Monoclonal antibodies against PD-L1 or CTLA4 have been developed to block binding to PD1 on native immune cells or CAR T cells [106]. Combination therapy of checkpoint inhibitors with CAR T-cell therapy has been tested in clinical trials with promising results. Checkpoint inhibitor therapy has been tested to determine whether it is more effective administered at the time of CAR T-cell infusion or at a certain time point post-infusion. Though effective in many patients regardless of treatment timeline, the best time of treatment is unclear [107]. Although combination therapy was effective in some patients, resistance did occur, indicating that there are other factors at play that are affecting CAR T-cell inefficacy [102].

Modifications have also been made to CAR T cells allowing them to evade the problems associated with PD1/PD-L1 interaction in tumors. In one study, an armored CAR was developed with the ability to secrete anti-PD1 scFvs when activated [108]. In a mouse model of both hematologic and solid tumors, their armored CAR T cell exhibited equal or better tumoricidal function compared with separate co-treatment of an anti-PD1 antibody and CAR T cell. In this therapeutic approach, the anti-PD1 scFvs remained localized to the tumor, unlike the systemic dispersal when administered in the traditional intravenous way, which limits potentially harmful immunosuppressive effects in other parts of the body [108]. Another way to alter checkpoint inhibition in CAR T cells is to make them resistant to PD-L1. PD-L1-resistant CAR T cells have been engineered by knocking out the PD1 gene using CRISPR/Cas9 technology in T cells before transduction [109–111]. Another

method of creating PD1-resistant CAR T cells involves engineering a chimeric PD1/CD28 receptor, which alters the response when extracellular PD1 is bound from an inhibitory signal to a positive CD28 costimulatory signal [112]. Both of these PD1-resistant CAR models have increased efficacy in mouse models, though they have yet to be tested in clinical trials.

4.2. CAR Variations

Many variations have been made to the structure or composition of CARs and CAR T cells to improve their efficacy in solid tumors, the extent of which is beyond this review (see cited reviews for extensive detail on many different CAR varieties and applications) [5,113–115]. These modifications range from multi-specific CARs which bind multiple antigens to logic gated CAR T cells to cytokine secreting CAR T cells and CARs engineered into other cell types besides T cells [5].

Cytokine-secreting CAR T cells are an important development in CAR T-cell construction, also known as 4th generation CAR T cells, armored CARs, or TRUCKs [116]. These CARs are engineered so that upon binding of the scFv and activation of the signaling domains, nuclear factor of activated T cells (NFAT, an important T-cell activation transcription factor) is activated, triggering production and release of a specific cytokine, depending on how it has been engineered [117]. Many cytokines have been tested for use in these CAR T cells, including IL-7, IL-12, IL-15, IL-18, IL-2, and combinations of them as well [116]. The specific release of cytokines when CAR T cells are activated helps to alter the immunosuppressive TME by affecting the immune cell populations present and CAR T-cell stimulation, to improve both CAR T-cell response and overall immune response against the tumor [118]. Many cytokine-secreting CAR T cells are currently being tested, and there is significant promise in the clinical application of this CAR variation (see other sources for more information on current trials) [116,119].

One CAR variation that shows special promise in solid tumors are CAR macrophages (CAR-Ms). The construct of a CAR remains the same in CAR-Ms, though different signaling and costimulatory domains are being experimented with, but the CAR is incorporated into a macrophage instead of a T cell [120]. Several innate features of macrophages lend them to CAR-M application in solid tumors [121]. Macrophages have increased homing abilities to find tumors because they upregulate CCR2, which binds CCL2 (a chemokine secreted by tumor cells) [122]. They also have important plasticity, where they can alter between M1- and M2-like phenotypes depending on their stimulation. Macrophages are also professional APCs and can phagocytose cancer cells and present their antigen to other immune cells, generating a more robust immune response. CAR-M research has shown that they often have increased infiltration ability into solid tumors, and they can reduce the immunosuppressive state in the tumor by influencing polarization of surrounding immune cells and changing the cytokine profile [121]. CAR-M therapy was shown to recruit T cells to the tumor and increase presentation of cancer antigen to these T cells [123]. Research into this application of CARs is still ongoing, but it shows promise in solving many of the problems CAR T cells have in solid tumors.

There are many developments in CAR T-cell therapy where the binding domain is altered from the normal scFv [5]. One of these variations that may prove influential in solid tumors is CAR T cells that bind and are activated by soluble factors rather than membrane-bound surface antigen on cancer cells. CAR T cells were recently modified to bind to various soluble antigens, including the CD19 ectodomain and TGF- β , with the potential to engineer receptors for various soluble ligands with relative ease [124,125]. The receptors for these CAR T cells are structurally different from a typical scFv, but receptor dimerization allows for a cytotoxic response to be initiated [124]. These CAR T cells influence the TME by binding secreted factors that induce activation. For example, TGF- β binding CAR T cells reprogram the response to this cytokine from an immunosuppressive response to an immune-stimulating response [124]. Another CAR T-cell altered binding domain is incorporation of an NK cell ligand, NKp44, the ligands for which are found almost

exclusively on and secreted by tumor cells [126,127]. One of these ligands is PDGF-DD, previously discussed as an NK cell tumor-recognizing receptor. These NKp44 CAR T cells offer another option for more widely directly targeting tumor cells, which often have more heterogeneous expression of surface antigen [127]. CAR T cells may also bind this ligand when secreted to influence the TME, as mentioned above. NKp44 CAR T cells show effective anti-tumor effects in a variety of pediatric tumors and in synovial sarcoma [126,128].

4.3. Oncolytic Viruses in Combination with CAR T Cells

One approach to overcoming immunosuppressive effects of the TME is to use oncolytic viruses as an adjuvant to induce the tumor to change from an immunosuppressive to inflammatory immune environment. Oncolytic viruses work through selective invasion and subsequent killing of tumor cells [129]. Antigen-presenting cells (APCs) are then recruited, activating the innate anti-tumor immune response [130]. These viruses cause immunogenic cell death (ICD) through release of PAMPs and DAMPs [131]. Sustained ICD causes activation of an immune response that alters the TME through increased infiltration of immune cells stimulated by the release of antigens from lysed tumor cells [132]. There is currently one oncolytic virus approved by the FDA (discussed further below), and there are over 400 clinical trials for varying oncolytic viruses which have achieved varying anti-tumor success both as monotherapies and in conjunction with other immunotherapies [133–135]. However, current discoveries suggest that oncolytic viruses as a monotherapy are not likely to be fully effective due to the heterogeneity of cancer and its complex, dynamic nature [129].

The only oncolytic virus currently approved by the FDA, talimogene laherparepvec (T-VEC), is derived from human herpes simplex virus 1 and engineered to preferentially infect melanoma cells [135,136]. It encodes a granulocyte macrophage colony-stimulating factor, which stimulates a direct anti-tumoral effect and a secondary activation of APCs, resulting in an innate and adaptive immune response. T-VEC was determined to be well tolerated and safe, with a built-in safety of still being susceptible to common anti-viral drugs, including acyclovir [137]. Clinical trials obtained around 27% overall response rates and were shown to reduce Treg and MDSC levels [138–140]. The effect of T-VEC on the TME suggests it has potential to stimulate the immune response in the tumor to allow CAR T cells to be more effective. Oncolytic viruses are currently being refined to improve their anti-tumor effect, especially in tandem with CAR T-cell therapies. These prospects are extensively discussed in a recent review by Mardi et al. [129].

One promising novel oncolytic adenovirus was engineered to be “armored” with the CD8+ T cell attracting chemokine CXCL1 and used in conjunction with CAR T-cell therapy [141]. The CXCL11 secretion was hypothesized to support CAR T-cell infiltration into the tumor and potentially increase infiltration of other lymphocytes expressing CXCR11. In an immunodeficient glioblastoma mouse model, the combined treatment of armored oncolytic adenovirus (oAd-CXCL11) with a B7H3 binding CAR T cell (B7H3.CAR-T) was shown to be significantly more effective at reducing tumor progression and even tumor elimination than either treatment alone. In a fully immunocompetent glioblastoma mouse model, the oAd-CXCL11 was combined with B7H3.CAR-T, and the combination was not only the most effective at reducing tumor progression and prolonging life of the mice but also increased infiltration of natural M1 macrophages, NK cells, and CD8+ T cells into the tumor, causing a shift in the TME profile. The combination of adenovirus-induced activation of the innate immune system and chemokine-induced lymphocyte infiltration proves a promising mechanism for altering the TME and increasing CAR T-cell infiltration and efficacy [141].

Oncolytic viruses, in conjunction with CAR T-cell therapy, provide a promising solution to several of the TME-associated challenges of CAR T cells. Generation of a natural immune response, as well as engineered cytokine and chemokine secretion, allow oncolytic viruses to improve CAR T-cell homing to tumors [129]. The alteration of the TME’s immune environment may also improve CAR T-cell longevity and efficacy. There are virtually limitless combinations of oncolytic viruses and CAR T cells that can be combined as a form

of personalized medicine for cancer patients [129]. These logical reasons make this combination therapy a promising method for targeted tumor destruction and TME alteration.

4.4. Metabolic Modifications

Modifications can be made to the CAR T cells themselves to improve metabolic function and overcome immunosuppression due to the unique metabolic profile of the TME. One mechanism is to use CRISPR/Cas9 to knockout the TGF- β II receptor in T cells before transduction to make them CAR T cells [142]. Both in vivo and in vitro the edited CAR T cells performed better at eliminating cancer cells through a mechanism of increasing metabolic capacity in glycolysis and oxidative phosphorylation, allowing them to metabolically outcompete cancer cells for resources [142,143]. A similar concept has been applied by others to knock out a variety of genes to improve glycolysis in T cells [144–146]. Though this method has shown promising results, it has yet to be translated to the clinic in CAR T-cell trials.

During the expansion phase of CAR T-cell generation, The CAR T cells can be cultured in nutrient restrictive media to mimic the environment the CAR T cells will encounter in the TME. T cells are plastic and can adjust their metabolic preferences depending on their environment during differentiation; thus, restrictive media may improve CAR T-cell longevity and efficacy in the glucose and glutamine-scarce TME [147]. In mouse models, CAR T cells expanded in glutamine and glucose-restrictive media had increased cytotoxic function when injected into the tumor [148,149]. This practice has promise, but characterizing the unique TME metabolic profile of each tumor and customizing the media to match may not be as practical in a clinical application [147].

In a similar vein, CAR T-cell treatment in conjunction with metabolic inhibitors can also improve CAR T-cell efficacy and persistence. PI3K inhibitors block the PI3K/AKT/mTOR pathway, which is regulated strictly in normal cells but heavily relied on for growth in cancer cells [150]. Several PI3K inhibitors have been approved for treatment of aggressive cancers, with other variations in different phases of trial [151]. The combination of PI3K inhibitors with CAR T cells has been shown to improve the reduction of tumor burden in mouse models, likely by reducing the nutrient scarcity burden placed on CAR T cells and improving their persistence [152].

5. Conclusions

CAR T cells are an important development in cancer treatment, with their clinical success in hematological malignancies showing much promise. However, solid tumor cancers present obstacles to CAR T cells due to the immunosuppressive TME mediated by pro-tumor cell populations, cytokine profiles, metabolic immunosuppression, vasculature, and more. Though these obstacles are real, research is ongoing to modify CAR T cells or use them in conjunction with other therapies to infiltrate and eliminate tumors more effectively by circumventing immunosuppressive characteristics of the TME (Table 2). This research will continue to expand, enabling obstacles facing CAR T-cell therapy in solid tumors to be overcome in the coming years.

Table 2. Overview of immunosuppressive effects on CAR T cells and advancements to overcome them.

Immunosuppressive TME Element	Effect on CAR T Cells	Methods of Overcoming the Limitation
Insufficient vasculature and “shell” surrounding tumors	CAR T-cell homing and tumor infiltration failure	Injection of CAR T cells into tumors, rather than intravenous delivery CAR macrophages
Immunosuppressive cytokine profiles	CAR T-cell exhaustion and anergy	Cytokine secreting CAR T cells and soluble ligand binding T cells

Table 2. Cont.

Immunosuppressive TME Element	Effect on CAR T Cells	Methods of Overcoming the Limitation
Tumor expression of PDL-1	CAR T-cell exhaustion and death	Checkpoint inhibitor co-treatment and CAR T cells modified to block or alter PD-1/PDL-1 response
High levels of tumor antigen	CAR T-cell exhaustion and anergy	Use of less differentiated T cells in CAR T cells production
Mutation to alter surface expression of neoantigens	Antigen escape	Bispecific and altered binding domain CAR T cells
Hostile metabolic environment	CAR T-cell exhaustion and decreased cytotoxicity	Genetic modification to CAR T-cell's metabolic processes Expansion phase media modifications (nutrient-limited media, inclusion of metabolic inhibitors)
High levels of immunosuppressive cell populations (Tregs, MDSCs, TAMs)	CAR T-cell anergy	Oncolytic virus co-treatment in conjunction with CAR T cells CAR macrophages

Author Contributions: A.C. manuscript writing and editing. M.T. and K.O. manuscript editing. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References

- Guedan, S.; Calderon, H.; Posey, A.D.; Maus, M.V. Engineering and Design of Chimeric Antigen Receptors. *Mol. Ther. Methods Clin. Dev.* **2019**, *12*, 145–156. [[CrossRef](#)] [[PubMed](#)]
- Hong, M.; Clubb, J.D.; Chen, Y.Y. Engineering CAR-T Cells for Next-Generation Cancer Therapy. *Cancer Cell* **2020**, *38*, 473–488. [[CrossRef](#)]
- Graham, C.; Hewitson, R.; Pagliuca, A.; Benjamin, R. Cancer immunotherapy with CAR-T cells—Behold the future. *Clin. Med.* **2018**, *18*, 324–328. [[CrossRef](#)] [[PubMed](#)]
- Neelapu, S.S.; Locke, F.L.; Bartlett, N.L.; Lekakis, L.J.; Miklos, D.B.; Jacobson, C.A.; Braunschweig, I.; Oluwole, O.O.; Siddiqi, T.; Lin, Y.; et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. *N. Engl. J. Med.* **2017**, *377*, 2531–2544. [[CrossRef](#)] [[PubMed](#)]
- Moreno, C.; Haynie, C.; Johnson, A.; Weber, K.S. Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer. *Biomedicines* **2022**, *10*, 1493. [[CrossRef](#)] [[PubMed](#)]
- Abramson, J.S. Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma. *Transfus. Med. Rev.* **2020**, *34*, 29–33. [[CrossRef](#)]
- Fujiwara, Y.; Kato, T.; Hasegawa, F.; Sunahara, M.; Tsurumaki, Y. The Past, Present, and Future of Clinically Applied Chimeric Antigen Receptor-T-Cell Therapy. *Pharmaceuticals* **2022**, *15*, 207. [[CrossRef](#)]
- Berdeja, J.G.; Madduri, D.; Usmani, S.Z.; Jakubowiak, A.; Agha, M.; Cohen, A.D.; Stewart, A.K.; Hari, P.; Htut, M.; Lesokhin, A.; et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b/2 open-label study. *Lancet* **2021**, *398*, 314–324. [[CrossRef](#)]
- Holstein, S.A.; Lunning, M.A. CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress. *Clin. Pharmacol. Ther.* **2020**, *107*, 112–122. [[CrossRef](#)]
- Lindo, L.; Wilkinson, L.H.; Hay, K.A. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy. *Front. Immunol.* **2020**, *11*, 618387. [[CrossRef](#)]
- Nallanthighal, S.; Heiserman, J.P.; Cheon, D.J. The Role of the Extracellular Matrix in Cancer Stemness. *Front. Cell Dev. Biol.* **2019**, *7*, 86. [[CrossRef](#)] [[PubMed](#)]
- Paolillo, M.; Schinelli, S. Extracellular Matrix Alterations in Metastatic Processes. *Int. J. Mol. Sci.* **2019**, *20*, 4947. [[CrossRef](#)]
- Bonnans, C.; Chou, J.; Werb, Z. Remodelling the extracellular matrix in development and disease. *Nat. Rev. Mol. Cell Biol.* **2014**, *15*, 786–801. [[CrossRef](#)] [[PubMed](#)]
- Wu, T.; Dai, Y. Tumor microenvironment and therapeutic response. *Cancer Lett.* **2017**, *387*, 61–68. [[CrossRef](#)]
- Kartikasari, A.E.R.; Huertas, C.S.; Mitchell, A.; Plebanski, M. Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis. *Front. Oncol.* **2021**, *11*, 692142. [[CrossRef](#)] [[PubMed](#)]

16. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. *Cell* **2011**, *144*, 646–674. [[CrossRef](#)]
17. Zuazo-Gaztelu, I.; Casanovas, O. Unraveling the Role of Angiogenesis in Cancer Ecosystems. *Front. Oncol.* **2018**, *8*, 248. [[CrossRef](#)]
18. Nagy, J.A.; Dvorak, H.F. Heterogeneity of the tumor vasculature: The need for new tumor blood vessel type-specific targets. *Clin. Exp. Metastasis* **2012**, *29*, 657–662. [[CrossRef](#)]
19. Lei, X.; Lei, Y.; Li, J.-K.; Du, W.-X.; Li, R.-G.; Yang, J.; Li, J.; Li, F.; Tan, H.-B. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. *Cancer Lett.* **2020**, *470*, 126–133. [[CrossRef](#)]
20. Farhood, B.; Najafi, M.; Mortezaee, K. CD8⁺ cytotoxic T lymphocytes in cancer immunotherapy: A review. *J. Cell. Physiol.* **2019**, *234*, 8509–8521. [[CrossRef](#)]
21. Ahrends, T.; Borst, J. The opposing roles of CD4⁺ T cells in anti-tumor immunity. *Immunology* **2018**, *154*, 574–581. [[CrossRef](#)] [[PubMed](#)]
22. Habif, G.; Crinier, A.; André, P.; Vivier, E.; Narni-Mancinelli, E. Targeting natural killer cells in solid tumors. *Cell. Mol. Immunol.* **2019**, *16*, 415–422. [[CrossRef](#)] [[PubMed](#)]
23. Michielsen, A.J.; Hogan, A.E.; Marry, J.; Tosetto, M.; Cox, F.; Hyland, J.M.; Sheahan, K.D.; O'Donoghue, D.P.; Mulcahy, H.E.; Ryan, E.J.; et al. Tumour tissue microenvironment can inhibit dendritic cell maturation in colorectal cancer. *PLoS ONE* **2011**, *6*, e27944. [[CrossRef](#)] [[PubMed](#)]
24. Aras, S.; Zaidi, M.R. TAMEless traitors: Macrophages in cancer progression and metastasis. *Br. J. Cancer* **2017**, *117*, 1583–1591. [[CrossRef](#)] [[PubMed](#)]
25. Coffelt, S.B.; Wellenstein, M.D.; de Visser, K.E. Neutrophils in cancer: Neutral no more. *Nat. Rev. Cancer* **2016**, *16*, 431–446. [[CrossRef](#)]
26. Croci, D.O.; Zacarias Fluck, M.F.; Rico, M.J.; Matar, P.; Rabinovich, G.A.; Scharovsky, O.G. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. *Cancer Immunol. Immunother.* **2007**, *56*, 1687–1700. [[CrossRef](#)] [[PubMed](#)]
27. Solinas, G.; Germano, G.; Mantovani, A.; Allavena, P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. *J. Leukoc. Biol.* **2009**, *86*, 1065–1073. [[CrossRef](#)]
28. DeNardo, D.G.; Ruffell, B. Macrophages as regulators of tumour immunity and immunotherapy. *Nat. Rev. Immunol.* **2019**, *19*, 369–382. [[CrossRef](#)]
29. Huang, X.; Li, Y.; Fu, M.; Xin, H.B. Polarizing Macrophages In Vitro. *Methods Mol. Biol.* **2018**, *1784*, 119–126. [[CrossRef](#)]
30. Lewis, C.; Murdoch, C. Macrophage responses to hypoxia: Implications for tumor progression and anti-cancer therapies. *Am. J. Pathol.* **2005**, *167*, 627–635. [[CrossRef](#)]
31. Bingle, L.; Lewis, C.E.; Corke, K.P.; Reed, M.W.; Brown, N.J. Macrophages promote angiogenesis in human breast tumour spheroids in vivo. *Br. J. Cancer* **2006**, *94*, 101–107. [[CrossRef](#)] [[PubMed](#)]
32. Nishie, A.; Ono, M.; Shono, T.; Fukushi, J.; Otsubo, M.; Onoue, H.; Ito, Y.; Inamura, T.; Ikezaki, K.; Fukui, M.; et al. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. *Clin. Cancer Res.* **1999**, *5*, 1107–1113. [[PubMed](#)]
33. Hotchkiss, K.A.; Ashton, A.W.; Klein, R.S.; Lenzi, M.L.; Zhu, G.H.; Schwartz, E.L. Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration. *Cancer Res.* **2003**, *63*, 527–533.
34. Dvorak, H.F. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. *N. Engl. J. Med.* **1986**, *315*, 1650–1659.
35. Qian, B.Z.; Pollard, J.W. Macrophage diversity enhances tumor progression and metastasis. *Cell* **2010**, *141*, 39–51. [[CrossRef](#)] [[PubMed](#)]
36. Law, A.M.K.; Valdes-Mora, F.; Gallego-Ortega, D. Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer. *Cells* **2020**, *9*, 561. [[CrossRef](#)]
37. Rodriguez-Garcia, A.; Palazon, A.; Noguera-Ortega, E.; Powell, D.J.; Guedan, S. CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape. *Front. Immunol.* **2020**, *11*, 1109. [[CrossRef](#)]
38. Srivastava, M.K.; Sinha, P.; Clements, V.K.; Rodriguez, P.; Ostrand-Rosenberg, S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. *Cancer Res.* **2010**, *70*, 68–77. [[CrossRef](#)]
39. Ostrand-Rosenberg, S. Myeloid-derived suppressor cells: More mechanisms for inhibiting antitumor immunity. *Cancer Immunol. Immunother.* **2010**, *59*, 1593–1600. [[CrossRef](#)]
40. Enblad, G.; Karlsson, H.; Gammelgård, G.; Wenthe, J.; Lövgren, T.; Amini, R.M.; Wikstrom, K.I.; Essand, M.; Savoldo, B.; Hallböök, H.; et al. A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia. *Clin. Cancer Res.* **2018**, *24*, 6185–6194. [[CrossRef](#)]
41. Sakaguchi, S.; Sakaguchi, N.; Asano, M.; Itoh, M.; Toda, M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. *J. Immunol.* **1995**, *155*, 1151–1164. [[PubMed](#)]
42. Kim, J.M.; Rasmussen, J.P.; Rudensky, A.Y. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. *Nat. Immunol.* **2007**, *8*, 191–197. [[CrossRef](#)] [[PubMed](#)]

43. Samstein, R.M.; Arvey, A.; Josefowicz, S.Z.; Peng, X.; Reynolds, A.; Sandstrom, R.; Neph, S.; Sabo, P.; Kim, J.M.; Liao, W.; et al. Foxp3 exploits a pre-existent enhancer landscape for regulatory T cell lineage specification. *Cell* **2012**, *151*, 153–166. [[CrossRef](#)] [[PubMed](#)]
44. Liyanage, U.K.; Moore, T.T.; Joo, H.G.; Tanaka, Y.; Herrmann, V.; Doherty, G.; Drebin, J.A.; Strasberg, S.M.; Eberlein, T.J.; Goedegebuure, P.S.; et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. *J. Immunol.* **2002**, *169*, 2756–2761. [[CrossRef](#)] [[PubMed](#)]
45. Wolf, D.; Wolf, A.M.; Rumpold, H.; Fiegl, H.; Zeimet, A.G.; Muller-Holzner, E.; Deibl, M.; Gastl, G.; Gunsilius, E.; Marth, C. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. *Clin. Cancer Res.* **2005**, *11*, 8326–8331. [[CrossRef](#)]
46. Wolf, D.; Sopper, S.; Pircher, A.; Gastl, G.; Wolf, A.M. Treg(s) in Cancer: Friends or Foe? *J. Cell. Physiol.* **2015**, *230*, 2598–2605. [[CrossRef](#)]
47. Facciabene, A.; Motz, G.T.; Coukos, G. T-regulatory cells: Key players in tumor immune escape and angiogenesis. *Cancer Res.* **2012**, *72*, 2162–2171. [[CrossRef](#)]
48. Kalluri, R. The biology and function of fibroblasts in cancer. *Nat. Rev. Cancer* **2016**, *16*, 582–598. [[CrossRef](#)]
49. Sahai, E.; Astsaturov, I.; Cukierman, E.; DeNardo, D.G.; Egeblad, M.; Evans, R.M.; Fearon, D.; Greten, F.R.; Hingorani, S.R.; Hunter, T.; et al. A framework for advancing our understanding of cancer-associated fibroblasts. *Nat. Rev. Cancer* **2020**, *20*, 174–186. [[CrossRef](#)]
50. LeBleu, V.S.; Kalluri, R. A peek into cancer-associated fibroblasts: Origins, functions and translational impact. *Dis. Model. Mech.* **2018**, *11*, dmm029447. [[CrossRef](#)]
51. Cannone, S.; Greco, M.R.; Carvalho, T.M.A.; Guizouarn, H.; Soriani, O.; Di Molfetta, D.; Tomasini, R.; Zeeberg, K.; Reshkin, S.J.; Cardone, R.A. Cancer Associated Fibroblast (CAF) Regulation of PDAC Parenchymal (CPC) and CSC Phenotypes Is Modulated by ECM Composition. *Cancers* **2022**, *14*, 3737. [[CrossRef](#)] [[PubMed](#)]
52. Jenkins, L.; Jungwirth, U.; Avgustinova, A.; Irvani, M.; Mills, A.; Haider, S.; Harper, J.; Isacke, C.M. Cancer-Associated Fibroblasts Suppress CD8+ T-cell Infiltration and Confer Resistance to Immune-Checkpoint Blockade. *Cancer Res.* **2022**, *82*, 2904–2917. [[CrossRef](#)] [[PubMed](#)]
53. Li, L.; Yu, R.; Cai, T.; Chen, Z.; Lan, M.; Zou, T.; Wang, B.; Wang, Q.; Zhao, Y.; Cai, Y. Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment. *Int. Immunopharmacol.* **2020**, *88*, 106939. [[CrossRef](#)] [[PubMed](#)]
54. Taniguchi, K.; Karin, M. NF- κ B, inflammation, immunity and cancer: Coming of age. *Nat. Rev. Immunol.* **2018**, *18*, 309–324. [[CrossRef](#)] [[PubMed](#)]
55. Grivennikov, S.; Karin, E.; Terzic, J.; Mucida, D.; Yu, G.Y.; Vallabhapurapu, S.; Scheller, J.; Rose-John, S.; Cheroutre, H.; Eckmann, L.; et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. *Cancer Cell* **2009**, *15*, 103–113. [[CrossRef](#)] [[PubMed](#)]
56. Kelly-Spratt, K.S.; Pitteri, S.J.; Gurley, K.E.; Liggitt, D.; Chin, A.; Kennedy, J.; Wong, C.-H.; Zhang, Q.; Buson, T.B.; Wang, H.; et al. Plasma proteome profiles associated with inflammation, angiogenesis, and cancer. *PLoS ONE* **2011**, *6*, e19721. [[CrossRef](#)]
57. Kim, R.; Emi, M.; Tanabe, K. Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responses. *Cancer Biol. Ther.* **2005**, *4*, 924–933. [[CrossRef](#)]
58. Dennis, K.L.; Blatner, N.R.; Gounari, F.; Khazaie, K. Current status of interleukin-10 and regulatory T-cells in cancer. *Curr. Opin. Oncol.* **2013**, *25*, 637–645. [[CrossRef](#)]
59. Syed, V. TGF- β Signaling in Cancer. *J. Cell. Biochem.* **2016**, *117*, 1279–1287. [[CrossRef](#)]
60. Barrow, A.D.; Edeling, M.A.; Trifonov, V.; Luo, J.; Goyal, P.; Bohl, B.; Bando, J.K.; Kim, A.H.; Walker, J.; Andahazy, M.; et al. Natural Killer Cells Control Tumor Growth by Sensing a Growth Factor. *Cell* **2018**, *172*, 534–548.e519. [[CrossRef](#)]
61. Pavlova, N.N.; Thompson, C.B. The Emerging Hallmarks of Cancer Metabolism. *Cell Metab.* **2016**, *23*, 27–47. [[CrossRef](#)] [[PubMed](#)]
62. Pavlova, N.N.; Zhu, J.; Thompson, C.B. The hallmarks of cancer metabolism: Still emerging. *Cell Metab.* **2022**, *34*, 355–377. [[CrossRef](#)] [[PubMed](#)]
63. Otto, W. On the origin of cancer cells. *Science* **1956**, *123*, 309–314. [[CrossRef](#)]
64. Shi, R.; Tang, Y.Q.; Miao, H. Metabolism in tumor microenvironment: Implications for cancer immunotherapy. *MedComm* **2020**, *1*, 47–68. [[CrossRef](#)]
65. Warburg, O.; Wind, F.; Negelein, E. The Metabolism of Tumors in the Body. *J. Gen. Physiol.* **1927**, *8*, 519–530. [[CrossRef](#)]
66. Liberti, M.V.; Locasale, J.W. The Warburg Effect: How Does It Benefit Cancer Cells? *Trends Biochem. Sci.* **2016**, *41*, 211–218. [[CrossRef](#)]
67. Altman, B.J.; Stine, Z.E.; Dang, C.V. From Krebs to clinic: Glutamine metabolism to cancer therapy. *Nat. Rev. Cancer* **2016**, *16*, 749. [[CrossRef](#)]
68. Hayes, C.; Donohoe, C.L.; Davern, M.; Donlon, N.E. The oncogenic and clinical implications of lactate induced immunosuppression in the tumour microenvironment. *Cancer Lett.* **2021**, *500*, 75–86. [[CrossRef](#)]
69. Angelin, A.; Gil-de-Gómez, L.; Dahiya, S.; Jiao, J.; Guo, L.; Levine, M.H.; Wang, Z.; Quinn, W.J.; Kopinski, P.K.; Wang, L.; et al. Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments. *Cell Metab.* **2017**, *25*, 1282–1293.e1287. [[CrossRef](#)]

70. Elia, I.; Haigis, M.C. Metabolites and the tumour microenvironment: From cellular mechanisms to systemic metabolism. *Nat. Metab.* **2021**, *3*, 21–32. [[CrossRef](#)]
71. Jing, X.; Yang, F.; Shao, C.; Wei, K.; Xie, M.; Shen, H.; Shu, Y. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. *Mol. Cancer* **2019**, *18*, 157. [[CrossRef](#)] [[PubMed](#)]
72. Hatfield, S.M.; Kjaergaard, J.; Lukashev, D.; Schreiber, T.H.; Belikoff, B.; Abbott, R.; Sethumadhavan, S.; Philbrook, P.; Ko, K.; Cannici, R.; et al. Immunological mechanisms of the antitumor effects of supplemental oxygenation. *Sci. Transl. Med.* **2015**, *7*, 277ra230. [[CrossRef](#)] [[PubMed](#)]
73. Parodi, M.; Raggi, F.; Cangelosi, D.; Manzini, C.; Balsamo, M.; Blengio, F.; Eva, A.; Varesio, L.; Pietra, G.; Moretta, L.; et al. Hypoxia Modifies the Transcriptome of Human NK Cells, Modulates Their Immunoregulatory Profile, and Influences NK Cell Subset Migration. *Front. Immunol.* **2018**, *9*, 2358. [[CrossRef](#)] [[PubMed](#)]
74. Lee, J.H.; Elly, C.; Park, Y.; Liu, Y.-C. E3 Ubiquitin Ligase VHL Regulates Hypoxia-Inducible Factor-1 α to Maintain Regulatory T Cell Stability and Suppressive Capacity. *Immunity* **2015**, *42*, 1062–1074. [[CrossRef](#)]
75. Corbet, C.; Feron, O. Tumour acidosis: From the passenger to the driver's seat. *Nat. Rev. Cancer* **2017**, *17*, 577–593. [[CrossRef](#)]
76. Colegio, O.R.; Chu, N.Q.; Szabo, A.L.; Chu, T.; Rhebergen, A.M.; Jairam, V.; Cyrus, N.; Brokowski, C.E.; Eisenbarth, S.C.; Phillips, G.M.; et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. *Nature* **2014**, *513*, 559–563. [[CrossRef](#)]
77. Brand, A.; Singer, K.; Koehl, G.E.; Koltz, M.; Schoenhammer, G.; Thiel, A.; Matos, C.; Bruss, C.; Klobuch, S.; Peter, K.; et al. LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. *Cell Metab.* **2016**, *24*, 657–671. [[CrossRef](#)]
78. Safarzadeh Kozani, P.; Rahbarizadeh, F. Addressing the obstacles of CAR T cell migration in solid tumors: Wishing a heavy traffic. *Crit. Rev. Biotechnol.* **2022**, *42*, 1079–1098. [[CrossRef](#)]
79. Skovgard, M.S.; Hocine, H.R.; Saini, J.K.; Moroz, M.; Bellis, R.Y.; Banerjee, S.; Morello, A.; Ponomarev, V.; Villena-Vargas, J.; Adusumilli, P.S. Imaging CAR T-cell kinetics in solid tumors: Translational implications. *Mol. Ther. Oncolytics* **2021**, *22*, 355–367. [[CrossRef](#)]
80. Bernhard, H.; Neudorfer, J.; Gebhard, K.; Conrad, H.; Hermann, C.; Nährig, J.; Fend, F.; Weber, W.; Busch, D.H.; Peschel, C. Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. *Cancer Immunol. Immunother.* **2008**, *57*, 271–280. [[CrossRef](#)]
81. Joyce, J.A.; Fearon, D.T. T cell exclusion, immune privilege, and the tumor microenvironment. *Science* **2015**, *348*, 74–80. [[CrossRef](#)] [[PubMed](#)]
82. Salmon, H.; Franciszkiwicz, K.; Damotte, D.; Dieu-Nosjean, M.C.; Validire, P.; Trautmann, A.; Mami-Chouaib, F.; Donnadieu, E. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. *J. Clin. Invest.* **2012**, *122*, 899–910. [[CrossRef](#)]
83. Piali, L.; Fichtel, A.; Terpe, H.J.; Imhof, B.A.; Gisler, R.H. Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. *J. Exp. Med.* **1995**, *181*, 811–816. [[CrossRef](#)]
84. Griffioen, A.W.; Damen, C.A.; Blijham, G.H.; Groenewegen, G. Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. *Blood* **1996**, *88*, 667–673. [[CrossRef](#)]
85. Klein, D. The Tumor Vascular Endothelium as Decision Maker in Cancer Therapy. *Front. Oncol.* **2018**, *8*, 367. [[CrossRef](#)]
86. Peranzoni, E.; Lemoine, J.; Vimeux, L.; Feuillet, V.; Barrin, S.; Kantari-Mimoun, C.; Bercovici, N.; Guérin, M.; Biton, J.; Ouakrim, H.; et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. *Proc. Natl. Acad. Sci. USA* **2018**, *115*, E4041–E4050. [[CrossRef](#)] [[PubMed](#)]
87. Wei, Y.H.; He, Y.Z.; Lin, X.Y.; Ren, F.X.; Zhu, H.B.; Cheng, Y.; Nan, Z.; Liu, Z.B.; Yu, J.Y.; Guo, X.J. Regional Injection of CAR-T Cells for the Treatment of Refractory and Recurrent Diffuse Large B Cell Lymphoma: A Case Report. *Front. Cell Dev. Biol.* **2020**, *8*, 333. [[CrossRef](#)] [[PubMed](#)]
88. Grosskopf, A.K.; Labanieh, L.; Klysz, D.D.; Roth, G.A.; Xu, P.; Adebowale, O.; Gale, E.C.; Jons, C.K.; Klich, J.H.; Yan, J.; et al. Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors. *Sci. Adv.* **2022**, *8*, eabn8264. [[CrossRef](#)]
89. Wherry, E.J.; Kurachi, M. Molecular and cellular insights into T cell exhaustion. *Nat. Rev. Immunol.* **2015**, *15*, 486–499. [[CrossRef](#)]
90. Wherry, E.J. T cell exhaustion. *Nat. Immunol.* **2011**, *12*, 492–499. [[CrossRef](#)]
91. DePeaux, K.; Delgoffe, G.M. Metabolic barriers to cancer immunotherapy. *Nat. Rev. Immunol.* **2021**, *21*, 785–797. [[CrossRef](#)] [[PubMed](#)]
92. Scharping, N.E.; Rivadeneira, D.B.; Menk, A.V.; Vignali, P.D.A.; Ford, B.R.; Rittenhouse, N.L.; Peralta, R.; Wang, Y.; DePeaux, K.; Poholek, A.C.; et al. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. *Nat. Immunol.* **2021**, *22*, 205–215. [[CrossRef](#)] [[PubMed](#)]
93. Yu, Y.-R.; Imrichova, H.; Wang, H.; Chao, T.; Xiao, Z.; Gao, M.; Rincon-Restrepo, M.; Franco, F.; Genolet, R.; Cheng, W.-C.; et al. Disturbed mitochondrial dynamics in CD8. *Nat. Immunol.* **2020**, *21*, 1540–1551. [[CrossRef](#)]
94. Vardhana, S.A.; Hwee, M.A.; Berisa, M.; Wells, D.K.; Yost, K.E.; King, B.; Smith, M.; Herrera, P.S.; Chang, H.Y.; Satpathy, A.T.; et al. Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. *Nat. Immunol.* **2020**, *21*, 1022–1033. [[CrossRef](#)] [[PubMed](#)]

95. Patsoukis, N.; Bardhan, K.; Chatterjee, P.; Sari, D.; Liu, B.; Bell, L.N.; Karoly, E.D.; Freeman, G.J.; Petkova, V.; Seth, P.; et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. *Nat. Commun.* **2015**, *6*, 6692. [[CrossRef](#)]
96. Ogando, J.; Sáez, M.E.; Santos, J.; Nuevo-Tapióles, C.; Gut, M.; Esteve-Codina, A.; Heath, S.; González-Pérez, A.; Cuezva, J.M.; Lacalle, R.A.; et al. PD-1 signaling affects cristae morphology and leads to mitochondrial dysfunction in human CD8. *J. Immunother. Cancer* **2019**, *7*, 151. [[CrossRef](#)]
97. Tkachev, V.; Goodell, S.; Otipari, A.W.; Hao, L.Y.; Franchi, L.; Glick, G.D.; Ferrara, J.L.; Byersdorfer, C.A. Programmed death-1 controls T cell survival by regulating oxidative metabolism. *J. Immunol.* **2015**, *194*, 5789–5800. [[CrossRef](#)]
98. Riley, J.L. PD-1 signaling in primary T cells. *Immunol. Rev.* **2009**, *229*, 114–125. [[CrossRef](#)]
99. Chan, J.D.; Lai, J.; Slaney, C.Y.; Kallies, A.; Beavis, P.A.; Darcy, P.K. Cellular networks controlling T cell persistence in adoptive cell therapy. *Nat. Rev. Immunol.* **2021**, *21*, 769–784. [[CrossRef](#)]
100. Sharma, P.; Hu-Lieskovan, S.; Wargo, J.A.; Ribas, A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. *Cell* **2017**, *168*, 707–723. [[CrossRef](#)]
101. Majzner, R.G.; Mackall, C.L. Tumor Antigen Escape from CAR T-cell Therapy. *Cancer Discov.* **2018**, *8*, 1219–1226. [[CrossRef](#)] [[PubMed](#)]
102. Lemoine, J.; Ruella, M.; Houot, R. Born to survive: How cancer cells resist CAR T cell therapy. *J. Hematol. Oncol.* **2021**, *14*, 199. [[CrossRef](#)] [[PubMed](#)]
103. Green, M.R.; Monti, S.; Rodig, S.J.; Juszczynski, P.; Currie, T.; O'Donnell, E.; Chapuy, B.; Takeyama, K.; Neubergh, D.; Golub, T.R.; et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. *Blood* **2010**, *116*, 3268–3277. [[CrossRef](#)] [[PubMed](#)]
104. Feucht, J.; Kayser, S.; Gorodezki, D.; Hamieh, M.; Döring, M.; Blaeschke, F.; Schlegel, P.; Bösmüller, H.; Quintanilla-Fend, L.; Ebinger, M.; et al. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. *Oncotarget* **2016**, *7*, 76902–76919. [[CrossRef](#)] [[PubMed](#)]
105. Park, S.H.; You, E.; Park, C.J.; Cho, Y.-U.; Jang, S.; Im, H.-J.; Seo, J.-J.; Park, H.-S.; Lee, J.-H. Increased expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets of bone marrow aspirates in patients with B-Lymphoblastic leukemia, especially in relapse and at diagnosis. *Cytom. B Clin. Cytom.* **2020**, *98*, 336–347. [[CrossRef](#)] [[PubMed](#)]
106. Ai, L.; Chen, J.; Yan, H.; He, Q.; Luo, P.; Xu, Z.; Yang, X. Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy. *Drug Des. Dev. Ther.* **2020**, *14*, 3625–3649. [[CrossRef](#)]
107. Jacobson, C.A.; Chavez, J.C.; Sehgal, A.R.; William, B.M.; Munoz, J.; Salles, G.; Munshi, P.N.; Casulo, C.; Maloney, D.G.; de Vos, S.; et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): A single-arm, multicentre, phase 2 trial. *Lancet Oncol.* **2022**, *23*, 91–103. [[CrossRef](#)]
108. Rafiq, S.; Yeku, O.O.; Jackson, H.J.; Purdon, T.J.; van Leeuwen, D.G.; Drakes, D.J.; Song, M.; Miele, M.M.; Li, Z.; Wang, P.; et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. *Nat. Biotechnol.* **2018**, *36*, 847–856. [[CrossRef](#)]
109. Rupp, L.J.; Schumann, K.; Roybal, K.T.; Gate, R.E.; Ye, C.J.; Lim, W.A.; Marson, A. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. *Sci. Rep.* **2017**, *7*, 737. [[CrossRef](#)]
110. Stadtmauer, E.A.; Fraietta, J.A.; Davis, M.M.; Cohen, A.D.; Weber, K.L.; Lancaster, E.; Mangan, P.A.; Kulikovskaya, I.; Gupta, M.; Chen, F.; et al. CRISPR-engineered T cells in patients with refractory cancer. *Science* **2020**, *367*, eaba7365. [[CrossRef](#)]
111. Ren, J.; Liu, X.; Fang, C.; Jiang, S.; June, C.H.; Zhao, Y. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition. *Clin. Cancer Res.* **2017**, *23*, 2255–2266. [[CrossRef](#)] [[PubMed](#)]
112. Liu, H.; Lei, W.; Zhang, C.; Yang, C.; Wei, J.; Guo, Q.; Guo, X.; Chen, Z.; Lu, Y.; Young, K.H.; et al. CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma. *Clin. Cancer Res.* **2021**, *27*, 473–484. [[CrossRef](#)] [[PubMed](#)]
113. Abbott, R.C.; Hughes-Parry, H.E.; Jenkins, M.R. To go or not to go? Biological logic gating engineered T cells. *J. Immunother. Cancer* **2022**, *10*, e004185. [[CrossRef](#)] [[PubMed](#)]
114. Miao, L.; Zhang, J.; Huang, B.; Zhang, Z.; Wang, S.; Tang, F.; Teng, M.; Li, Y. Special Chimeric Antigen Receptor (CAR) Modifications of T Cells: A Review. *Front. Oncol.* **2022**, *12*, 832765. [[CrossRef](#)] [[PubMed](#)]
115. Han, X.; Wang, Y.; Wei, J.; Han, W. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy. *J. Hematol. Oncol.* **2019**, *12*, 128. [[CrossRef](#)]
116. Chmielewski, M.; Abken, H. TRUCKS: The fourth generation of CARs. *Expert Opin. Biol. Ther.* **2015**, *15*, 1145–1154. [[CrossRef](#)]
117. Yeku, O.O.; Brentjens, R.J. Armored CAR T-cells: Utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. *Biochem. Soc. Trans.* **2016**, *44*, 412–418. [[CrossRef](#)]
118. Yeku, O.O.; Purdon, T.J.; Koneru, M.; Spriggs, D.; Brentjens, R.J. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. *Sci. Rep.* **2017**, *7*, 10541. [[CrossRef](#)]
119. Hawkins, E.R.; D'Souza, R.R.; Klampatsa, A. Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy. *Biologics* **2021**, *15*, 95–105. [[CrossRef](#)]

120. Wang, S.; Yang, Y.; Ma, P.; Zha, Y.; Zhang, J.; Lei, A.; Li, N. CAR-macrophage: An extensive immune enhancer to fight cancer. *EBioMedicine* **2022**, *76*, 103873. [[CrossRef](#)]
121. Morrissey, M.A.; Williamson, A.P.; Steinbach, A.M.; Roberts, E.W.; Kern, N.; Headley, M.B.; Vale, R.D. Chimeric antigen receptors that trigger phagocytosis. *Elife* **2018**, *7*, e36688. [[CrossRef](#)] [[PubMed](#)]
122. Hao, Q.; Vadgama, J.V.; Wang, P. CCL2/CCR2 signaling in cancer pathogenesis. *Cell Commun. Signal.* **2020**, *18*, 82. [[CrossRef](#)] [[PubMed](#)]
123. Klichinsky, M.; Ruella, M.; Shestova, O.; Lu, X.M.; Best, A.; Zeeman, M.; Schmierer, M.; Gabrusiewicz, K.; Anderson, N.R.; Petty, N.E.; et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. *Nat. Biotechnol.* **2020**, *38*, 947–953. [[CrossRef](#)] [[PubMed](#)]
124. Chang, Z.L.; Lorenzini, M.H.; Chen, X.; Tran, U.; Bangayan, N.J.; Chen, Y.Y. Rewiring T-cell responses to soluble factors with chimeric antigen receptors. *Nat. Chem. Biol.* **2018**, *14*, 317–324. [[CrossRef](#)] [[PubMed](#)]
125. Chang, Z.L.; Hou, A.J.; Chen, Y.Y. Engineering primary T cells with chimeric antigen receptors for rewired responses to soluble ligands. *Nat. Protoc.* **2020**, *15*, 1507–1524. [[CrossRef](#)]
126. Kasahara, Y.; Shin, C.; Kubo, N.; Mihara, K.; Iwabuchi, H.; Takachi, T.; Imamura, M.; Saitoh, A.; Imai, C. Development and characterisation of NKp44-based chimeric antigen receptors that confer T cells with NK cell-like specificity. *Clin. Transl. Immunol.* **2020**, *9*, e1147. [[CrossRef](#)]
127. Parodi, M.; Favoreel, H.; Candiano, G.; Gaggero, S.; Sivori, S.; Mingari, M.C.; Moretta, L.; Vitale, M.; Cantoni, C. NKp44-NKp44 Ligand Interactions in the Regulation of Natural Killer Cells and Other Innate Lymphoid Cells in Humans. *Front. Immunol.* **2019**, *10*, 719. [[CrossRef](#)]
128. Murayama, Y.; Kasahara, Y.; Kubo, N.; Shin, C.; Imamura, M.; Oike, N.; Ariizumi, T.; Saitoh, A.; Baba, M.; Miyazaki, T.; et al. NKp44-based chimeric antigen receptor effectively redirects primary T cells against synovial sarcoma. *Transl. Oncol.* **2022**, *25*, 101521. [[CrossRef](#)]
129. Mardi, A.; Shirokova, A.V.; Mohammed, R.N.; Keshavarz, A.; Zekiy, A.O.; Thangavelu, L.; Mohamad, T.A.M.; Marofi, F.; Shomali, N.; Zamani, A.; et al. Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction. *Cancer Cell Int.* **2022**, *22*, 168. [[CrossRef](#)]
130. Kaufman, H.L.; Kohlhapp, F.J.; Zloza, A. Oncolytic viruses: A new class of immunotherapy drugs. *Nat. Rev. Drug Discov.* **2016**, *15*, 660. [[CrossRef](#)]
131. Galluzzi, L.; Buqué, A.; Kepp, O.; Zitvogel, L.; Kroemer, G. Immunogenic cell death in cancer and infectious disease. *Nat. Rev. Immunol.* **2017**, *17*, 97–111. [[CrossRef](#)] [[PubMed](#)]
132. Harrington, K.; Freeman, D.J.; Kelly, B.; Harper, J.; Soria, J.C. Optimizing oncolytic virotherapy in cancer treatment. *Nat. Rev. Drug Discov.* **2019**, *18*, 689–706. [[CrossRef](#)] [[PubMed](#)]
133. Li, K.; Zhao, Y.; Hu, X.; Jiao, J.; Wang, W.; Yao, H. Advances in the clinical development of oncolytic viruses. *Am. J. Transl. Res.* **2022**, *14*, 4192–4206. [[PubMed](#)]
134. Garmaroudi, G.A.; Karimi, F.; Naeini, L.G.; Kokabian, P.; Givtaj, N. Therapeutic Efficacy of Oncolytic Viruses in Fighting Cancer: Recent Advances and Perspective. *Oxidative Med. Cell. Longev.* **2022**, *2022*, 3142306. [[CrossRef](#)] [[PubMed](#)]
135. Pol, J.; Kroemer, G.; Galluzzi, L. First oncolytic virus approved for melanoma immunotherapy. *Oncoimmunology* **2016**, *5*, e1115641. [[CrossRef](#)]
136. Andtbacka, R.H.; Kaufman, H.L.; Collichio, F.; Amatruda, T.; Senzer, N.; Chesney, J.; Delman, K.A.; Spitler, L.E.; Puzanov, I.; Agarwala, S.S.; et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients with Advanced Melanoma. *J. Clin. Oncol.* **2015**, *33*, 2780–2788. [[CrossRef](#)] [[PubMed](#)]
137. Hu, J.C.; Coffin, R.S.; Davis, C.J.; Graham, N.J.; Groves, N.; Guest, P.J.; Harrington, K.J.; James, N.D.; Love, C.A.; McNeish, I.; et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. *Clin. Cancer Res.* **2006**, *12*, 6737–6747. [[CrossRef](#)]
138. Senzer, N.N.; Kaufman, H.L.; Amatruda, T.; Nemunaitis, M.; Reid, T.; Daniels, G.; Gonzalez, R.; Glaspy, J.; Whitman, E.; Harrington, K.; et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. *J. Clin. Oncol.* **2009**, *27*, 5763–5771. [[CrossRef](#)]
139. Kaufman, H.L.; Bines, S.D. OPTIM trial: A Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. *Future Oncol.* **2010**, *6*, 941–949. [[CrossRef](#)]
140. Kaufman, H.L.; Kim, D.W.; DeRaffele, G.; Mitcham, J.; Coffin, R.S.; Kim-Schulze, S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. *Ann. Surg. Oncol.* **2010**, *17*, 718–730. [[CrossRef](#)]
141. Wang, G.; Zhang, Z.; Zhong, K.; Wang, Z.; Yang, N.; Tang, X.; Li, H.; Lu, Q.; Wu, Z.; Yuan, B.; et al. CXCL11-armed oncolytic adenoviruses enhance CAR-T cells therapeutic efficacy and reprogram tumor microenvironment in glioblastoma. *Mol. Ther.* **2022**, *31*, 1. [[CrossRef](#)]
142. Tang, N.; Cheng, C.; Zhang, X.; Qiao, M.; Li, N.; Mu, W.; Wei, X.F.; Han, W.; Wang, H. TGF- β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. *JCI Insight* **2020**, *5*, e133977. [[CrossRef](#)] [[PubMed](#)]
143. Cattley, R.T.; Lee, M.; Boggess, W.C.; Hawse, W.F. Transforming growth factor β (TGF- β) receptor signaling regulates kinase networks and phosphatidylinositol metabolism during T-cell activation. *J. Biol. Chem.* **2020**, *295*, 8236–8251. [[CrossRef](#)] [[PubMed](#)]

144. Ma, R.; Ji, T.; Zhang, H.; Dong, W.; Chen, X.; Xu, P.; Chen, D.; Liang, X.; Yin, X.; Liu, Y.; et al. A Pck1-directed glycogen metabolic program regulates formation and maintenance of memory CD8. *Nat. Cell Biol.* **2018**, *20*, 21–27. [[CrossRef](#)] [[PubMed](#)]
145. Doedens, A.L.; Phan, A.T.; Stradner, M.H.; Fujimoto, J.K.; Nguyen, J.V.; Yang, E.; Johnson, R.S.; Goldrath, A.W. Hypoxia-inducible factors enhance the effector responses of CD8⁺ T cells to persistent antigen. *Nat. Immunol.* **2013**, *14*, 1173–1182. [[CrossRef](#)] [[PubMed](#)]
146. Zhang, M.; Jin, X.; Sun, R.; Xiong, X.; Wang, J.; Xie, D.; Zhao, M. Optimization of metabolism to improve efficacy during CAR-T cell manufacturing. *J. Transl. Med.* **2021**, *19*, 499. [[CrossRef](#)]
147. Rad SM, A.H.; Halpin, J.C.; Mollaei, M.; Smith Bell, S.W.J.; Hirankarn, N.; McLellan, A.D. Metabolic and Mitochondrial Functioning in Chimeric Antigen Receptor (CAR)-T Cells. *Cancers* **2021**, *13*, 1229. [[CrossRef](#)]
148. Nabe, S.; Yamada, T.; Suzuki, J.; Toriyama, K.; Yasuoka, T.; Kuwahara, M.; Shiraishi, A.; Takenaka, K.; Yasukawa, M.; Yamashita, M. Reinforce the antitumor activity of CD8. *Cancer Sci.* **2018**, *109*, 3737–3750. [[CrossRef](#)]
149. Amini, A.; Veraitch, F. Glucose deprivation enriches for central memory T cells during chimeric antigen receptor-T cell expansion. *Cytotherapy* **2019**, *21*, S30–S31. [[CrossRef](#)]
150. Saravia, J.; Raynor, J.L.; Chapman, N.M.; Lim, S.A.; Chi, H. Signaling networks in immunometabolism. *Cell Res.* **2020**, *30*, 328–342. [[CrossRef](#)]
151. Yang, J.; Nie, J.; Ma, X.; Wei, Y.; Peng, Y.; Wei, X. Targeting PI3K in cancer: Mechanisms and advances in clinical trials. *Mol. Cancer* **2019**, *18*, 26. [[CrossRef](#)] [[PubMed](#)]
152. Zheng, W.; O’Hear, C.E.; Alli, R.; Basham, J.H.; Abdelsamed, H.A.; Palmer, L.E.; Jones, L.L.; Youngblood, B.; Geiger, T.L. PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells. *Leukemia* **2018**, *32*, 1157–1167. [[CrossRef](#)] [[PubMed](#)]